Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US-2015051380-A1 · Feb 19, 2015 · US
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
US9492553B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9492553-B2 |
| Application number | US-201414254067-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 16, 2014 |
| Priority date | Feb 1, 2008 |
| Publication date | Nov 15, 2016 |
| Grant date | Nov 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D) p I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
First claim
Opening claim text (preview).
We claim: 1. A drug-linker reagent comprising the structure: wherein X 4 is a linker comprising a thiol reactive functional group selected from maleimide, iodoacetamide, bromoacetamide, vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, and isothiocyanate. 2. The drug-linker reagent of claim 1 wherein X 4 is a linker comprising maleimide. 3. The drug-linker reagent of claim 1 wherein X 4 is a linker comprising bromoacetamide. 4. The drug-linker reagent of claim 1 wherein X 4 is a linker comprising pyridyl disulfide.
Assignees
Inventors
Classifications
the antibody targeting a determinant of a tumour cell · CPC title
- A61K47/42Primary
Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Antineoplastic agents · CPC title
- C07D498/14Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9492553B2 cover?
- The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D) p I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and o…
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K47/42. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).